Immunogenicity and Biological Activity of Chimeric Proteins Composed of FimH, CsgA, and PapG Adhesins Against Uropathogenic Escherichia coli
Microorganisms · 15.11.2026 · 14 (11) · 2649
DOI: 10.3390/microorganisms14112649 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microorganisms, online erschienen am 15.11.2026. Verfasst von Sara A. Ochoa und 9 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hospital Infantil de México “Federico Gómez”, Secretaría de Ciencia, Humanidades, Tecnología e Innovación.
Abstract (Originalsprache)
Urinary tract infections (UTIs) are a major global health care challenge, and uropathogenic Escherichia coli (UPEC) is the primary etiological agent. The emergence of multidrug-resistant UPEC strains increasingly compromises therapeutic management, highlighting the need for novel prophylactic strategies. However, UPEC exhibits high fimbrial diversity and can upregulate alternative chaperone–usher systems to maintain adherence when a single colonization pathway is disrupted. To overcome this adaptive pathogenicity, we evaluated the immunogenicity and functional efficacy of three engineered trimeric fusion proteins that differ in their topological orientation: designated PFC, FCP, and CPF. They comprise the key surface adhesins FimH, CsgA, and PapG. A stratified cross-sectional analysis was conducted using 62 pediatric UPEC clinical strains to determine their phylogenetic groups and fimbrial genotypes through multiplex PCR. In patient cohorts, local (urine, n = 62) and systemic (serum, n = 16 per group) antibody profiles against the recombinant antigens were quantified through indirect ELISA. The functional blocking capacity of hyperimmune rabbit polyclonal antibodies was assessed through in vitro adherence inhibition assays with HTB-5 bladder epithelial cells infected with the reference strain CFT073. Genomic characterization revealed 100% prevalence of the individual core colonization factors fimH and csgA across strains. However, PCR-based detection of these loci offers only theoretical gene-target coverage within this sample collection without establishing active in vivo antigen expression or functional surface accessibility during infection. Genotypically, the baseline core target combination (fimH + csgA + papG-) was present in 58.1% (36/62) of the total cohort, whereas the complex virulence genotype fimH + csgA + papGII was identified in 40.3% (25/62) of the strains and showed strict tropism for the extraintestinal phylogroups B2 and D, which represented 42% (26/62) and 38% (24/62) of the overall population, respectively. Within phylogroup D, the (papAH) structural gene was detected in 29.2% (7/24) of its strains. This specific subset of seven strains positive for the (fimH + csgA + papGII) genotype within phylogroup D accounted for 11.3% of the total 62 clinical isolates analyzed, highlighting its epidemiological significance in severe pediatric infections. In patients with active UPEC infection, a robust humoral response was observed compared with that in healthy controls, as demonstrated by significantly elevated urinary IgG and IgA titers (p < 0.0001). Serum analysis demonstrated that the PFC chimera effectively distinguished UPEC-induced UTIs from UTIs induced by other uropathogens, revealing significantly higher IgA (p = 0.0008) and IgG (p < 0.0001) levels, thereby establishing its potential value as a systemic diagnostic immunogenic antigen target platform. Crucially, functional cell-adherence assays revealed that α-PFC antibodies produced the greatest reduction in bacterial attachment, limiting residual colonization to 22.7% (p < 0.0001). This optimized configuration significantly outperformed alternative structural chimeric configurations (α-FCP, p = 0.0011; α-CPF, p = 0.0008), suggesting that the specific PFC topological orientation may minimize steric hindrance between receptor-binding loops during multifimbrial interactions. The engineered PFC trimeric protein is a structurally optimized antigen platform with potential for future broad-spectrum prophylactic strategies against recurrent UTIs ; however, its in vivo immunogenicity, protective clearance, and cross-strain efficacy remain to be determined.
Förderung
- Hospital Infantil de México “Federico Gómez”
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación
Zitieren
APA
Ochoa, S. A., Vazquez-Gutierrez, I. G., Flores-Oropeza, M. A., Hernández-Castro, R., Arellano-Galindo, J., Villavicencio-Carrisoza, O., Helguera-Repetto, A. C., Flores-Encarnacion, M., Zavala-Vega, S., & Xicohtencatl-Cortés, J. (2026). Immunogenicity and Biological Activity of Chimeric Proteins Composed of FimH, CsgA, and PapG Adhesins Against Uropathogenic Escherichia coli. Microorganisms, 14(11), 2649. https://doi.org/10.3390/microorganisms14112649
Vancouver
Ochoa SA, Vazquez-Gutierrez IG, Flores-Oropeza MA, Hernández-Castro R, Arellano-Galindo J, Villavicencio-Carrisoza O, et al. Immunogenicity and Biological Activity of Chimeric Proteins Composed of FimH, CsgA, and PapG Adhesins Against Uropathogenic Escherichia coli. Microorganisms. 2026;14(11):2649. doi:10.3390/microorganisms14112649
BibTeX
@article{Ochoa2026,
author = {Ochoa, Sara A. and Vazquez-Gutierrez, Isabel G. and Flores-Oropeza, Marco A. and Hernández-Castro, Rigoberto and Arellano-Galindo, José and Villavicencio-Carrisoza, Oscar and Helguera-Repetto, Addy Cecilia and Flores-Encarnacion, Marcos and Zavala-Vega, Sergio and Xicohtencatl-Cortés, Juan},
title = {Immunogenicity and Biological Activity of Chimeric Proteins Composed of FimH, CsgA, and PapG Adhesins Against Uropathogenic Escherichia coli},
journal = {Microorganisms},
year = {2026},
volume = {14},
number = {11},
pages = {2649},
doi = {10.3390/microorganisms14112649}
}
EUVIMED